Compare TMCI & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMCI | IAE |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 97.0M |
| IPO Year | 2021 | N/A |
| Metric | TMCI | IAE |
|---|---|---|
| Price | $3.91 | $9.22 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.77 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 88.2K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.17 | $6.65 |
| 52 Week High | $7.78 | $9.27 |
| Indicator | TMCI | IAE |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 60.51 |
| Support Level | $2.46 | $8.79 |
| Resistance Level | $4.47 | $9.24 |
| Average True Range (ATR) | 0.45 | 0.23 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 16.67 | 89.04 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.